SUMMARY Eight patients with chronic open-angle glaucoma who had an intraocular pressure >24 mm Hg at some time during the day while taking timolol 0.5% twice daily were given the fixed ratio combination of timolol 0.5% with pilocarpine 2% (TP2) twice daily. By comparing full 24-hour diurnal curves on timolol with those on TP2 it was possible to show that all patients except one (at a single timepoint) had an IOP <22 mm Hg when changed to TP2. The mean TOPs, the area under the diurnal pressure curve, and the diurnal variation were all significantly lower on TP2 twice daily than on timolol 0-5% twice daily.
It has been reported'-that up to 30% of patients with chronic open-angle glaucoma (COAG) will not experience fully adequate reduction of intraocular pressure (IOP) on timolol 0-5% twice daily. The commonest and most rational additional agent used with timolol is pilocarpine. Pilocarpine is usually prescribed three or four times a day because its duration of action is only 6-8 hours. In a previous study4 it was shown that, whereas timolol 0-5% plus pilocarpine 2% or 4% twice daily both improved IOP control significantly in patients not controlled (-22 mm Hg) on timolol 0-5% twice daily, increasing the frequency of the pilocarpine from twice to four times a day had no beneficial effect on the level of control or on its smoothness. Thus it was shown that it was possible to combine timolol with pilocarpine in a twice daily regimen. The present study was undertaken to evaluate the efficacy of a fixed ratio combination of timolol and pilocarpine twice daily in patients with COAG whose IOP was not controlled by timolol 0-5% twice daily. In particular we wished to compare the diurnal variation on the two regimens, since this would best confirm or negate the value of this fixed combination in glaucoma management.
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Materials and methods
The timolol and pilocarpine combination contained timolol 0-5% and pilocarpine 2% (TP2) at pH 6-8 produced by mixing a ready mixed timolol and pilocarpine solution with a buffering solution to raise the pH of the mixture just prior to being issued to the patients. It is known that formulated in this way the TP2 mixture is stable for four weeks.
Patients with primary open-angle glaucoma (POAG) were selected who had been on timolol 0-5% (T) alone twice daily for at least two weeks and had an IOP in both eyes greater than 24 Adverse experiences were sought throughout the study. The investigator was asked to evaluate their severity and their relationship to the test medication. Any patient reporting photopsias or an increase in floaters during the study was to be taken off TP2, excluded from further participation in this study, fully examined, and assigned to appropriate clinical follow-up.
All analyses were performed using the patient's worst eye defined as the eye with the greater IOP on day 1 at 0600 (the last diurnal curve measurement before TP2 was administered). If the IOP was the same in both eyes, the right eye was chosen. To evaluate efficacy the baseline (T) diurnal curve was compared with that on TP2. Comparisons were made by comparing the area under the diurnal curves, by timepoint analysis of differences in IOP, by the smoothness of the diurnal curves (<5 mm Hg range being used as a reference point).
POWER AND SAMPLE SIZE From a previous study4 it was calculated that, with a standard deviation for IOP change of 3-0 mm Hg, eight patients would be sufficient to detect a 3-5 mm Hg difference in IOP between T and TP, with 80% power (a=0-05, two tailed). In fact in this study the actual pooled standard deviation of the change from baseline of 2-2 mm Hg gave 80% power to detect a change of 2 Analyses were performed as described above. The analysis of IOPs at each timepoint for both treatments addresses the efficacy 12 hours after the previous dose both at night and in the morning. Examinations on day -1 (the last day on timolol 0-5% twice daily as single therapy) at 1800 and on day 1 at 0600 (12 hours after the last dose of timolol 0 5% and immediately prior to the first dose of TP2) measured the 12-hour efficacy of T. the 12-hour efficacy of TP2 was measured on day 14 at 1800 and day 15 at 0600.
The data for all patients are shown in Table 1 . The mean IOPs at each timepoint are summarised in Table 2 and shown graphically in Fig. 1 . The difference between the mean IOP on T and that on TP2 is significant (p-.001) at all timepoints. This is reflected further by the means of the areas under the diurnal curves. The mean area under the curves for the worst eye was 575-4 (SD 22-1) mm Hg/h on T and 428 3 (SD 47. 1) mm Hg/h on TP2. The mean difference was significant (p-.0 01).
Smoothness of diurnal control was indicated by the diurnal variation. Only one patient (no. 6) did not have a smoother curve while on TP2 than on T, having a range of 3 mm Hg for each ( Table 1) . The mean reduction in diurnal variation for the eight patients' worst eyes was significant (p-0.05): the mean diurnal variation for T was 4-9 mm Hg and for TP2 was 1-9 mm Hg.
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No adverse experiences were reported, but five and one each of photopsias and eye irritation. Except patients reported a total of 10 ocular symptoms when for one report of 'night blindness' all the ocular receiving TP2. There were three instances of head-symptoms occurred on the first day of treatment with ache, three of 'night blindness' (difficulty in seeing in TP2 and had disappeared by day 14. One case of reduced light due to miosis), two of blurred vision, 'night blindness' was not reported on day 1 but was except one at one timepoint had the IOP controlled at all timepoints after receiving TP2. For all patients reported on day 14. All of the ocular symptoms were there was significantly greater control of IOP after mild in severity. There were no changes in visual they received TP2 than with T. acuity of either eye between day -1 (on T) and day 14
The smoothness of the diurnal curve was assessed (on TP2). adverse symptoms or ocular signs were noted. Ten There is a potential for bias in this study, since the ocular symptoms were reported; all were mild and, investigator would be clearly aware that the patients except for one case of 'night blindness' had diswere on the test medication TP2. There is no way of appeared by day 14. 'Night blindness' is a descriptive disguising a miosis to an ophthalmologist and thus no term describing reduced visual function in poor satisfactory way of controlling this study without illumination. In this study it is probable that, since all introducing a third active agent, for example pilocar-the patients were asymptomatic before receiving TP2 pine alone, which because of the time required for the symptoms experienced were due to the introductimolol washout would be to an undetermined extent tion of pilocarpine into their regimen. The symptoms additive and thus a rather confounded control agent. reported have all been reported on pilocarpine.' A comparison of activity of TP2 with pilocarpine has
The results of this study confirm findings in a been reported elsewhere.' previous study conducted by the same investigator1
From comparison with pretreatment IOPs all when 24 patients who had been on timolol received patients except patient 4 in the right eye had shown concomitant therapy of timolol 0-5% and pilocarpine some reduction in IOP when treated with timolol 2% or if necessary pilocarpine 4%. Pilocarpine (2% 0-5% twice daily.
or 4%) was administered twice or four times a day
Comparison of the diurnal curves showed signifi-concomitantly with timolol 0-5% twice daily. In cant lowering of IOP at all timepoints when patients patients who received concomitant therapy the IOP received TP2 in comparison with the same timepoints was reduced significantly in comparison with timolol when patients received T. This held true when we 0-5% alone. The patients receiving concomitant examined the mean IOP of the worst eye and under therapy also showed a smoother diurnal curve than the diurnal data curve. When all six timepoints for when they received timolol 0-5%. In addition the individual patients were examined, reductions in IOP study showed that there was no statistical difference at every timepoint were seen after patients had been between twice a day and four times a day dosing with Fixed ratio combination oftimolol andpilocarpine pilocarpine when used concomitantly with timolol.
In conducting the present study we hoped to show that a similar quality of IOP control could be obtained using a fixed combination of TP2 to that shown in the previous study using concomitant timolol pilocarpine. To make real comparisons a further study using combination and concomitant administration in a randomly allocated, doublemasked design would be required. The present study does, however, confirm the smooth nature of IOP control on TP2 twice daily in patients whose IOP was inadequately controlled on timolol 0-5% twice daily.
Pilocarpine is usually administered every six hours; even if it is administered concomitantly only twice a day with timolol 0-5%, the patient is still required to administer four drops, that is, two of timolol and two of pilocarpine. With TP2 the patient administers only one drop twice a day. Since compliance with a pilocarpine regimen has been shown to be poor, with patients administering a mean of only 76% of the prescribed doses and 30% of patients compressing their doses into 12 hours of the day8 it is likely that the use of a timolol pilocarpine combination twice daily will achieve better control and improved compliance in patients with glaucoma. 
